Aimmune, a clinical-stage biopharmaceutical company, is developing desensitization treatments for people with food allergies. We aim to help protect patients by reducing the risk of life-threatening reactions due to accidental exposure to food allergens.

Working to Address an Unmet Need in Food Allergy

- Food allergy is a disease in which exposure to a food triggers a harmful immune response, such as anaphylaxis, which can be life-threatening.¹
- More than 15 million Americans¹⁻³ and more than 17 million Europeans⁴ have food allergies. In the U.S. alone, more than 1.7 million children are believed to have a peanut allergy.²⁻⁵
- Eight major food allergens – milk, egg, peanut, tree nuts, wheat, soy, fish and shellfish – are responsible for most of the serious food allergy reactions in the U.S.¹
- Allergies to peanut, tree nuts, fish and shellfish are generally lifelong.¹
- Food allergies are currently managed through strict avoidance of food allergens and early recognition and treatment of allergic reactions.⁶
- Even trace amounts of a food allergen can cause a reaction.⁷⁻¹² Each year in the U.S., 200,000 people require emergency medical care for allergic reactions to food.¹³

CODIT™: Our Investigational Approach to Treating Food Allergies

- Our CODIT (Characterized Oral Desensitization ImmunoTherapy) approach is intended to be an optimized approach to food allergy treatment.
- The CODIT protocol involves gradual, controlled up-dosing followed by ongoing, low-dose maintenance.
- Our CODIT approach is intended to support food allergy products under development.

<table>
<thead>
<tr>
<th>PROGRAM</th>
<th>PRE-IND</th>
<th>PHASE 1/2*</th>
<th>PHASE 3</th>
<th>APPROVED</th>
</tr>
</thead>
<tbody>
<tr>
<td>AR101 (PEANUT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AR201 (EGG)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AR301 (WALNUT)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

First Application of CODIT: AR101, an Investigational Drug for Peanut Allergy

- AR101 is Aimmune’s investigational characterized, oral biologic drug maintaining the protein profile found in peanuts.
- Fast Track Designation, and Breakthrough Designation in the 4-17 age group, allow for expedited FDA review.
- Pivotal Phase 3 clinical trial PALISADE enrolled more than 550 peanut-allergic participants ages 4-55 in the U.S., Canada and Europe; top-line data reported in February 2018.
References:


